Respiratory imaging technology specialist 4DMedical (ASX: 4DX) has entered into a commercial agreement with UC San Diego Health (UCSD) for the clinical use of cardiothoracic imaging software solution CT:VQ.
The deal is expected to strengthen UCSD's imaging portfolio and position it at the forefront of functional lung imaging, providing a contrast-free, high-resolution alternative to traditional nuclear medicine two-part ventilation/perfusion (VQ) scans.
Under the terms, the health center will employ CT:VQ under a structured launch framework with introductory pricing to support early clinical adoption and workflow establishment, before transitioning to full commercial terms.
Commercialisation strategy
The new deal represents continued validation of 4DMedical's commercialisation strategy which has previously seen the company secure three of America's most respected academic medical centers as clients since CT:VQ received US Food and Drug Administration clearance in August.
Teams at Stanford University, the University of Miami, and the Cleveland Clinic have been recognised globally for their clinical excellence and cardiothoracic innovation, adopting CT:VQ as the new standard of care for VQ imaging.
Value proposition
The deployments demonstrate the software’s compelling clinical value proposition in eliminating the need for radioisotope and contrast administration, providing superior image resolution compared to nuclear medicine, seamlessly integrating into existing CT imaging workflows and enabling access to reimbursement pathways that support sustainable clinical adoption.
The expanding network powers 4DMedical’s strategic approach of establishing reference sites at prestigious US institutions to create a solid foundation for broader market adoption.
Accurate diagnoses
4DMedical founder and chief executive officer Andreas Fouras said CT:VQ would help UCSD radiologists to make accurate diagnoses with greater sensitivity and specificity.
“UCSD is consistently ranked in the Top 10 US institutions for pulmonology and lung surgery and is home to a world-class cardiothoracic imaging program — the adoption of CT:VQ represents a powerful validation of our technology and the strength of our go-to-market execution,” he said.
“Our distribution partnership with Philips and our growing commercial pipeline has given us unstoppable momentum in establishing CT:VQ as the new standard of care in pulmonary imaging.”
